Brazil Pharma and Healthcare Sector Report 2022-2023

The COVID-19 pandemic underlined the inefficiencies of the Brazilian pharmaceutical and healthcare sector. In drug manufacturing, many pharmaceutical companies took a hit in profitability. They struggled to meet demand as global supply chains were disrupted. The absence of a local comprehensive pharmaceutical supply chain depends on imported active pharmaceutical ingredients (APIs) for drug production. Moreover, Brazil has a long history of insufficient spending in its public health system. So when the health emergency hit, Brazil was among the countries reporting the highest death toll. As of October 2021, Brazil ranks eighth globally for most COVID-19-related deaths per million people. The government reacted to the pandemic with extraordinary expenditures in 2020 and 2021. But looking at the short- and medium-term, health spending will be tight, as the macroeconomic conditions present challenges.

This report provides a complete and detailed analysis of the healthcare and pharmaceutical sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the healthcare and pharmaceutical sector in Brazil
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in Brazil
• Crystallise the forces both driving and restraining this sector in Brazil
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Brazil
• Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels)

See below for a complete table of report contents: